PEPCID AC 10 MG
FAMOTIDINE : 10 MG · DIN 02185938 · MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
Health Canada status: MARKETED
What is PEPCID AC?
PEPCID AC 10 MG contains FAMOTIDINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02185938, held by MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PEPCID AC used for?
Treatment and prevention of acid indigestion, heartburn, sour or upset stomach, including symptoms associated with food/beverage consumption or nocturnal symptoms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is PEPCID AC called?
The same molecule, FAMOTIDINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FAMOSAN | Latin | Czechia |
| famodar | Latin | Bahrain, Saudi Arabia |
| Famotidine Amarox | Latin | Saudi Arabia |
| FAMOGEN | Latin | Saudi Arabia |
| FAMOPSIN | Latin | Bahrain |
| ULCERAN | Latin | Bahrain |
| Famodine | Latin | Saudi Arabia |
| Famotidin Genericon | Latin | Iceland |
| Famotidin STADA | Latin | Iceland |
| Famotidine for oral suspension | Latin | Saudi Arabia |
| QUAMATEL | Latin | Czechia |
| ULCIDINE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02185938 |
|---|---|
| Brand name | PEPCID AC |
| Generic / active ingredient | FAMOTIDINE : 10 MG |
| Manufacturer | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02BA03 FAMOTIDINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Nov-2025 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02185938 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2185938 |
| Brand name | PEPCID AC |
| Active ingredient / INN | FAMOTIDINE : 10 MG |
| ATC code | A02BA03 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC |
How is it administered?
Adults/Children 12+: 10-20 mg for relief or 10-15 min before food/drink for prevention. Max 2 tablets/24 hours. Do not exceed 2 weeks continuous treatment without medical consultation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11 of full monograph).
How is it supplied?
10 mg: Boxes of 30 and 60 in PVC/Aluminum blisters. 20 mg: Boxes of 5, 10, 25, 50, 80, and 120 in blisters.
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | 10 mg: Boxes of 30 and 60 in PVC/Aluminum blisters. 20 mg: Boxes of 5, 10, 25, 50, 80, and 120 in blisters. |
| Storage | Not explicitly stated in provided text (refer to section 11 of full monograph). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to famotidine or any ingredient in the formulation. Cross-sensitivity with other H2-receptor antagonists has been observed.
Warnings and precautions
Consult physician for difficulty swallowing, weight loss, or severe vomiting. CNS effects reported in renal insufficiency. Avoid driving if dizziness or somnolence occurs.
Is FAMOTIDINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by OMEGA LABORATORIES LIMITED (Tier 3 shortage FAMOTIDINE OMEGA -(WITHOUT PRESERVATIVE)" aria-label="Actual Tier 3 shortage FAMOTIDINE OMEGA -(WITHOUT), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A02BA03 FAMOTIDINE. 17 of 68 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONTROLLER MAXIMUM STRENGTH | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02538350 |
| AG-FAMOTIDINE | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02509970 |
| AG-FAMOTIDINE | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02509989 |
| FAMOTIDINE | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02549107 |
| FAMOTIDINE | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02351102 |
| FAMOTIDINE | 40 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02351110 |
| FAMOTIDINE | 40 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02549115 |
| FAMOTIDINE OMEGA -(WITH PRESERVATIVE,BENZYL ALCOHOL) | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02247745 |
| FAMOTIDINE OMEGA -(WITHOUT PRESERVATIVE) | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02247735 |
| JAMP FAMOTIDINE | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02507749 |
Who else supplies FAMOTIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FAMOTIDINE appears in 69 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does FAMOTIDINE cost around the world?
FAMOTIDINE is listed on 11 national price registers Nexara tracks, across 184 pack listings published on 10 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 5 | 112 | 03 Sep 2026 |
| Saudi Arabia | public | 11 | 21 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 9 | 18 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 2 | 7 | 03 Sep 2026 |
| Bahrain | retail (max) | 3 | 6 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 6 | 6 | 03 Sep 2026 |
| Australia | ex-manufacturer | 2 | 4 | 08 Sep 2026 |
| Morocco | PPV (public price) | 3 | 4 | 05 Sep 2026 |
| United Arab Emirates | public | 2 | 2 | 31 Aug 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Iceland | max wholesale | 2 | 2 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.